- Home
- RRC vs ROIV Comparison
RRC vs ROIV Comparison
Compare RRC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRC
- ROIV
- Stock Information
- Founded
- RRC 1976
- ROIV 2014
- Country
- RRC United States
- ROIV United Kingdom
- Employees
- RRC N/A
- ROIV N/A
- Industry
- RRC Oil & Gas Production
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- RRC Energy
- ROIV Health Care
- Exchange
- RRC Nasdaq
- ROIV Nasdaq
- Market Cap
- RRC 8.7B
- ROIV 8.6B
- IPO Year
- RRC N/A
- ROIV N/A
- Fundamental
- Price
- RRC $35.95
- ROIV $17.28
- Analyst Decision
- RRC Hold
- ROIV Strong Buy
- Analyst Count
- RRC 18
- ROIV 8
- Target Price
- RRC $42.12
- ROIV $19.94
- AVG Volume (30 Days)
- RRC 3.0M
- ROIV 7.4M
- Earning Date
- RRC 10-28-2025
- ROIV 11-11-2025
- Dividend Yield
- RRC 1.00%
- ROIV N/A
- EPS Growth
- RRC 0.32
- ROIV N/A
- EPS
- RRC 1.98
- ROIV N/A
- Revenue
- RRC $2,799,229,500.00
- ROIV $23,233,000.00
- Revenue This Year
- RRC $29.73
- ROIV N/A
- Revenue Next Year
- RRC $13.75
- ROIV $200.91
- P/E Ratio
- RRC $18.17
- ROIV N/A
- Revenue Growth
- RRC 19.93
- ROIV N/A
- 52 Week Low
- RRC $28.99
- ROIV $8.73
- 52 Week High
- RRC $43.50
- ROIV $17.33
- Technical
- Relative Strength Index (RSI)
- RRC 45.42
- ROIV 82.30
- Support Level
- RRC $35.38
- ROIV $15.91
- Resistance Level
- RRC $37.64
- ROIV $16.39
- Average True Range (ATR)
- RRC 1.38
- ROIV 0.52
- MACD
- RRC -0.37
- ROIV 0.03
- Stochastic Oscillator
- RRC 12.47
- ROIV 97.92
About RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.